RAD51C and breast cancer: Although in total RAD51C CNV had slightly higher frequency in the cases, this remained under statistical significance, even when combined with the previously published results from the Southern Finnish cohort (14/4794, 0.3% in cases with breast cancer vs. 2/2502, 0.1% in controls, P = 0.07, OR = 3.67, 95% CI = 0.83–16.12).